Paper42974396PubMed
Identification of B-cell maturation antigen (BCMA)-targeting peptides and selective drug delivery to multiple myeloma using peptide-targeted DM1 prodrug-loaded nanoparticles.
Hwang G and 4 others. Nanoscale Adv, 2026.
Cite this record
ConductScience Library. Identification of B-cell maturation antigen (BCMA)-targeting peptides and selective drug delivery to multiple myeloma using peptide-targeted DM1 prodrug-loaded nanoparticles. Papers, record 42974396. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/42974396
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Identification of B-cell maturation antigen (BCMA)-targeting peptides and selective drug delivery to multiple myeloma using peptide-targeted DM1 prodrug-loaded nanoparticles.
- Journal
- Nanoscale Adv
- Year
- 2026
- Publication types
- Journal Article
- Revised in PubMed
- 2026-11-05
Source PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
References37
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 38072962 | BCMA-targeted bortezomib nanotherapy improves therapeutic efficacy, overcomes resistance, and modulates the immune microenvironment in multiple myeloma. | Blood Cancer J | 2023 | https://conductscience.org/library/papers/38072962 | PubMed |
| 2 | 35661166 | Teclistamab in Relapsed or Refractory Multiple Myeloma. | N Engl J Med | 2022 | https://conductscience.org/library/papers/35661166 | PubMed |
| 3 | 27127303 | APRIL and BCMA promote human multiple myeloma growth and immunosuppression in the bone marrow microenvironment. | Blood | 2016 | https://conductscience.org/library/papers/27127303 | PubMed |
| 4 | 31473250 | Optimizing design parameters of a peptide targeted liposomal nanoparticle in an in vivo multiple myeloma disease model after initial evaluation in vitro. | J Control Release | 2019 | https://conductscience.org/library/papers/31473250 | PubMed |
| 5 | 23237506 | Regulatory roles of the tumor necrosis factor receptor BCMA. | Crit Rev Immunol | 2012 | https://conductscience.org/library/papers/23237506 | PubMed |
| 6 | 23841107 | Functionalized liposome purification via Liposome Extruder Purification (LEP). | Analyst | 2013 | https://conductscience.org/library/papers/23841107 | PubMed |
| 7 | 33138841 | In vivo evaluation of CD38 and CD138 as targets for nanoparticle-based drug delivery in multiple myeloma. | J Hematol Oncol | 2020 | https://conductscience.org/library/papers/33138841 | PubMed |
| 8 | 37313276 | Management of Ocular Toxicity in Patients Receiving Belantamab Mafodotin. | J Adv Pract Oncol | 2023 | https://conductscience.org/library/papers/37313276 | PubMed |
| 9 | 32276005 | Engineering peptide-targeted liposomal nanoparticles optimized for improved selectivity for HER2-positive breast cancer cells to achieve enhanced in vivo efficacy. | J Control Release | 2020 | https://conductscience.org/library/papers/32276005 | PubMed |
| 10 | 37582952 | Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results. | Nat Med | 2023 | https://conductscience.org/library/papers/37582952 | PubMed |
| 11 | 37995307 | Perspectives on the Treatment of Multiple Myeloma. | Oncologist | 2024 | https://conductscience.org/library/papers/37995307 | PubMed |
| 12 | 31859245 | Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study. | Lancet Oncol | 2020 | https://conductscience.org/library/papers/31859245 | PubMed |
| 13 | 22829966 | Rationally engineered nanoparticles target multiple myeloma cells, overcome cell-adhesion-mediated drug resistance, and show enhanced efficacy in vivo. | Blood Cancer J | 2012 | https://conductscience.org/library/papers/22829966 | PubMed |
| 14 | 38943315 | Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management. | Am J Hematol | 2024 | https://conductscience.org/library/papers/38943315 | PubMed |
| 15 | 25953704 | Potent anti-tumor response by targeting B cell maturation antigen (BCMA) in a mouse model of multiple myeloma. | Mol Oncol | 2015 | https://conductscience.org/library/papers/25953704 | PubMed |
| 16 | 25128717 | Nanoparticle multivalency counterbalances the ligand affinity loss upon PEGylation. | J Control Release | 2014 | https://conductscience.org/library/papers/25128717 | PubMed |
| 17 | 38961036 | Multiple myeloma: signaling pathways and targeted therapy. | Mol Biomed | 2024 | https://conductscience.org/library/papers/38961036 | PubMed |
| 18 | 37075614 | Anti-BCMA surface engineered biomimetic photothermal nanomissile enhances multiple myeloma cell apoptosis and overcomes the disturbance of NF-κB signaling in vivo. | Biomaterials | 2023 | https://conductscience.org/library/papers/37075614 | PubMed |
| 19 | 38961233 | Just scratching the surface: novel treatment approaches for multiple myeloma targeting cell membrane proteins. | Nat Rev Clin Oncol | 2024 | https://conductscience.org/library/papers/38961233 | PubMed |
| 20 | 37793771 | Efficacy and safety of single-agent belantamab mafodotin versus pomalidomide plus low-dose dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-3): a phase 3, open-label, randomised study. | Lancet Haematol | 2023 | https://conductscience.org/library/papers/37793771 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Cited by
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/42974396
GET https://conductscience.org/api/papers/v1/42974396/references?page=2